BMRN BioMarin Pharmaceutical Inc.

+0.81  (+1%)
Previous Close 82.35
Open 83.46
Price To Book 5
Market Cap 14833432318
Shares 178,372,202
Volume 2,067,788
Short Ratio
Av. Daily Volume 1,032,859

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 2Q 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data due end of 2019.
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Duchenne Muscular Dystrophy (DMD)
Phase 1/2 update May 22, 2018 noted 97% decrease in bleeding rate. Further data due May 2019 with BLA filing due 2H 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 2 commencement of dosing announced June 14, 2018.
Achondroplasia - young children

Latest News

  1. Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline
  2. Forbes Names BioMarin 4th Best Midsize Employer in America
  3. As Nasdaq 100 hits record, Apple and Intel could still be buys, says expert
  4. New Strong Sell Stocks for April 16th
  5. 8 Stocks May Jump on Takeovers as Market Nears Peak
  6. FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year
  7. See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
  8. Does Sangamo Have the Best Gene Therapy Program Now?
  9. Elon Musk’s CEO pay-to-worker ratio is the highest ever recorded — how it compares at other tech companies
  10. BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET
  11. Were Hedge Funds Right About BioMarin Pharmaceutical Inc. (BMRN) ?
  12. New Strong Sell Stocks for March 29th
  13. S&P Fights Past Growth Concerns to Reclaim 2800
  14. 3 Stocks to Buy Ahead of the Next Market Crash
  15. Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report?
  16. Analysts Are Mostly Positive on BioMarin Pharmaceutical in March
  17. S.F. hotel demand bubbles over, spilling out into the rest of the Bay Area
  18. Boeing Keeps Dow from Joining Rally